{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:47:39Z","timestamp":1791996459891,"version":"4.4.0"},"reference-count":40,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI147765-04"],"award-info":[{"award-number":["R01-AI147765-04"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01-AI069923-20"],"award-info":[{"award-number":["U01-AI069923-20"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01-AI172064"],"award-info":[{"award-number":["U01-AI172064"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01-AI174268-02"],"award-info":[{"award-number":["U01-AI174268-02"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","award":["405578\/2024-5"],"award-info":[{"award-number":["405578\/2024-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funda\u00e7\u00e3o Jos\u00e9 Silveira"},{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis preventive therapy (TPT) is critical in interrupting progression to disease, transmission and reducing incidence rates. Nonetheless, high costs have been barriers towards the expansion of shorter patient-friendly drug regimens. In 2019, a Unitaid-led deal reduced rifapentine costs by over 70%, facilitating Brazil\u2019s implementation of 3 months of rifapentine+isoniazid (3HP), a short-course TPT regimen, in its public health system. We evaluated the health and economic impact of Brazil\u2019s implementation of this patient-friendly regimen for short-course TPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed surveillance data on 171\u2009174 individuals initiating TPT from January 2019 to December 2024. A mixed-effects spatiotemporal Bayesian model estimated quarterly TPT initiation trends under (1) observed 3HP rollout versus a no-3HP counterfactual (Q3 2021\u2013Q4 2024) and (2) projected universal 3HP coverage (Q1 2025\u2013Q4 2027) versus extended no-3HP adoption. Cost-effectiveness analysis quantified active tuberculosis (TB) cases and disability-adjusted life-years (DALYs) averted, alongside costs, incremental cost-effectiveness ratios, net monetary benefits (NMBs) and return on investment of TPT under each 3HP coverage scenario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2022 to 2024, 3HP scale-up produced 37 508.4 (95% credible intervals (CrIs) 31 405.2 to 43\u2009631.6) additional TPT initiations, averted an estimated 15\u2009002 DALYs (95% CrI 8985.6 to 21\u2009031.15) and yielded NMBs of US$122.7\u2009million (95% CrI US$63.8 to US$198.2\u2009million). Under a proposed universal coverage (2025\u20132027), projected gains included 72 080.1 (95% CrI 62 323.7 to 81\u2009836.4) additional individuals starting TPT, with subsequent 26\u2009139 DALYs averted (95% CrI 14 117 to 38 762) and NMBs of US$214.5\u2009million (95% CrI US$103.0 to US$362.8\u2009million), indicating strong economic dominance over no-3HP adoption. Finally, TPT with 3HP\u2019s implementation was estimated to return US$1.31 (95% CrI US$0.97 to US$1.62) to the health system for every US$1 invested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Brazil, large-scale implementation of a patient-friendly short-course regimen (3HP) was effective and likely cost-saving for a resource-strained public health system. Our evaluation provides robust, real-world evidence that implementing this regimen improved TPT coverage and completion nationwide while reducing costs and TB disease burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2025-021546","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:26:14Z","timestamp":1776875174000},"page":"e021546","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Programmatic impact and cost-effectiveness of scaling up the short-course 3HP regimen for tuberculosis preventive treatment in Brazil"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9499-7929","authenticated-orcid":false,"given":"Klauss","family":"Villalva-Serra","sequence":"first","affiliation":[{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Bahia, Brazil"},{"name":"Laborat\u00f3rio de Pesquisa Cl\u00ednica e Translacional, Instituto Gon\u00e7alo Moniz, Funda\u00e7\u00e3o Oswaldo Cruz, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Barreto-Duarte","sequence":"additional","affiliation":[{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Bahia, Brazil"},{"name":"Laborat\u00f3rio de Pesquisa Cl\u00ednica e Translacional, Instituto Gon\u00e7alo Moniz, Funda\u00e7\u00e3o Oswaldo Cruz, Salvador, Brazil"},{"name":"Instituto de Pesquisa Cl\u00ednica e Translacional, Faculdade Zarns, Clariens Educa\u00e7\u00e3o, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno M","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Bahia, Brazil"},{"name":"Laborat\u00f3rio de An\u00e1lise e Visualiza\u00e7\u00e3o de Dados, Funda\u00e7\u00e3o Oswaldo Cruz, Porto Velho, Brazil"},{"name":"Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur T L","family":"Queiroz","sequence":"additional","affiliation":[{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Bahia, Brazil"},{"name":"Laborat\u00f3rio de Pesquisa Cl\u00ednica e Translacional, Instituto Gon\u00e7alo Moniz, Funda\u00e7\u00e3o Oswaldo Cruz, Salvador, Brazil"},{"name":"Instituto de Pesquisa Cl\u00ednica e Translacional, Faculdade Zarns, Clariens Educa\u00e7\u00e3o, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Croda","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Federal University of Mato Grosso do Sul, Campo Grande, Brazil"},{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Campo Grande, Mato Grosso do Sul, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria C","family":"Rolla","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Pesquisa Cl\u00ednica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afr\u00e2nio L","family":"Kritski","sequence":"additional","affiliation":[{"name":"Programa Acad\u00eamico de Tuberculose, Universidade Federal do Rio de Janeiro Faculdade de Medicina, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R","family":"Sterling","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Cordeiro-Santos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil"},{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil"},{"name":"Curso de Medicina, Universidade Nilton Lins, Manaus, Amazonas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Ara\u00fajo-Pereira","sequence":"additional","affiliation":[{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Bahia, Brazil"},{"name":"Laborat\u00f3rio de Pesquisa Cl\u00ednica e Translacional, Instituto Gon\u00e7alo Moniz, Funda\u00e7\u00e3o Oswaldo Cruz, Salvador, Brazil"},{"name":"Instituto de Pesquisa Cl\u00ednica e Translacional, Faculdade Zarns, Clariens Educa\u00e7\u00e3o, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-3811","authenticated-orcid":false,"given":"Bruno B","family":"Andrade","sequence":"additional","affiliation":[{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Bahia, Brazil"},{"name":"Laborat\u00f3rio de Pesquisa Cl\u00ednica e Translacional, Instituto Gon\u00e7alo Moniz, Funda\u00e7\u00e3o Oswaldo Cruz, Salvador, Brazil"},{"name":"Instituto de Pesquisa Cl\u00ednica e Translacional, Faculdade Zarns, Clariens Educa\u00e7\u00e3o, Salvador, Brazil"},{"name":"Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026042206250766000_11.4.e021546.1","unstructured":"World Health Organization . Global tuberculosis report 2024. 2024. Available: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024"},{"key":"2026042206250766000_11.4.e021546.2","unstructured":"World Health Organization . Tuberculosis resurges as top infectious disease killer. 2024. Available: https:\/\/www.who.int\/news\/item\/29-10-2024-tuberculosis-resurges-as-top-infectious-disease-killer"},{"key":"2026042206250766000_11.4.e021546.3","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1016\/S2214-109X(23)00251-6","article-title":"Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis","volume":"11","author":"Ryckman","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2026042206250766000_11.4.e021546.4","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.lana.2024.100963","article-title":"Impact of strategic public health interventions to reduce tuberculosis incidence in Brazil: a Bayesian structural time-series scenario analysis","volume":"41","author":"Villalva-Serra","year":"2025","journal-title":"The Lancet Regional Health - Americas"},{"key":"2026042206250766000_11.4.e021546.5","doi-asserted-by":"publisher","DOI":"10.5588\/pha.14.0089"},{"key":"2026042206250766000_11.4.e021546.6","unstructured":"Unitaid, IMPAACT4TB Consortium . IMPAACT4TB consortium. negotiation reduces price, expands access to tuberculosis treatment. 2019. Available: https:\/\/unitaid.org\/news-blog\/negotiation-reduces-price-expands-access-to-tuberculosis-treatment\/"},{"key":"2026042206250766000_11.4.e021546.7","unstructured":"Unitaid, IMPAACT4TB Consortium . 250,000 patients to benefit from free access to short-course TB prevention treatment across seven countries. 2023. Available: https:\/\/unitaid.org\/news-blog\/250000-patients-to-benefit-from-free-access-to-short-course-tb-prevention-treatment-across-seven-countries\/"},{"key":"2026042206250766000_11.4.e021546.8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6908a1"},{"key":"2026042206250766000_11.4.e021546.9","first-page":"44","article-title":"A trajet\u00f3ria da rifapentina para o tratamento da tuberculose latente no Brasil: incorpora\u00e7\u00e3o no Sistema \u00danico de Sa\u00fade e perspectivas para a produ\u00e7\u00e3o local","volume":"23","author":"Mendes","year":"2024","journal-title":"An Inst Hig Med Trop (Lisb)"},{"key":"2026042206250766000_11.4.e021546.10","unstructured":"Brazilian M of H . Epidemiological report - tuberculosis 2025. Bras\u00edlia, 2025. Available: https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/boletins-epidemiologicos\/2025\/boletim-epidemiologico-tuberculose-2025\/view"},{"key":"2026042206250766000_11.4.e021546.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-022-14766-6","article-title":"Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review","volume":"22","author":"Lai","year":"2022","journal-title":"BMC Public Health"},{"key":"2026042206250766000_11.4.e021546.12","unstructured":"Minist\u00e9rio da Sa\u00fade B . RESOLU\u00c7\u00c3O no 466, conselho nacional de sa\u00fade resolu\u00e7\u00e3o no 466, de 12 de dezembro de 2012. 2012 Available: https:\/\/www.inca.gov.br\/sites\/ufu.sti.inca.local\/files\/\/media\/document\/\/resolucao-cns-466-12.pdf"},{"key":"2026042206250766000_11.4.e021546.13","unstructured":"Secretaria de Vigil\u00e2ncia em Sa\u00fade . Protocolo de vigil\u00e2ncia da infec\u00e7\u00e3o latente pelo mycobacterium tuberculosis no Brasil. Bras\u00edlia, 2022. Available: www.saude.gov.br\/svs"},{"key":"2026042206250766000_11.4.e021546.14","unstructured":"Health and Environmental Surveillance Secretariat - Ministry of Health Brazil . Boletim epidemiol\u00f3gico - tratamento da infec\u00e7\u00e3o latente pelo mycobacterium tuberculosis no Brasil, 2018-2023. Bras\u00edlia, 2025."},{"key":"2026042206250766000_11.4.e021546.15","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00914-6"},{"key":"2026042206250766000_11.4.e021546.16","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Rubio V . 2020 Bayesian inference with INLA. Available: https:\/\/www.taylorfrancis.com\/books\/mono\/10.1201\/9781315175584\/bayesian-inference-inla-virgilio-gomez-rubio","DOI":"10.1201\/9781315175584"},{"key":"2026042206250766000_11.4.e021546.17","first-page":"2082","article-title":"The use of controls in interrupted time series studies of public health interventions","volume":"47","author":"Lopez Bernal","year":"2018","journal-title":"Int J"},{"key":"2026042206250766000_11.4.e021546.18","doi-asserted-by":"crossref","unstructured":"Coutinho I , Alves LC , Werneck GL , et al . The impact of the COVID-19 pandemic in tuberculosis preventive treatment in Brazil: a retrospective cohort study using secondary data. Lancet Reg Health Am 2023;19. doi:10.1016\/j.lana.2023.100444","DOI":"10.1016\/j.lana.2023.100444"},{"key":"2026042206250766000_11.4.e021546.19","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Ferrari","year":"2024","journal-title":"The Lancet"},{"key":"2026042206250766000_11.4.e021546.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004361","article-title":"Quantifying gaps in the tuberculosis care cascade in Brazil: A mathematical model study using national program data","volume":"21","author":"Emani","year":"2024","journal-title":"PLoS Med"},{"key":"2026042206250766000_11.4.e021546.21","doi-asserted-by":"crossref","first-page":"e1446","DOI":"10.1016\/S2214-109X(24)00221-3","article-title":"Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study","volume":"12","author":"van Lieshout Titan","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026042206250766000_11.4.e021546.22","unstructured":"Brazilian Ministry of Health . SIGTAP - sistema de gerenciamento da tabela de procedimentos, medicamentos e opm do sus. 2025. Available: http:\/\/sigtap.datasus.gov.br\/tabela-unificada\/app\/sec\/inicio.jsp"},{"key":"2026042206250766000_11.4.e021546.23","unstructured":"De VS , Nacional P , Controle D . Manual de recomenda\u00e7\u00f5es para o controle da tuberculose no brasil 2014. 2014. Available: www.saude.gov.br\/"},{"key":"2026042206250766000_11.4.e021546.24","unstructured":"Controladoria Geral da Uni\u00e3o \u2013 CGU . Manual da plataforma integrada de ouvidoria e acesso \u00e0 informa\u00e7\u00e3o - fala.br. 2020. Available: https:\/\/www.gov.br\/cnen\/pt-br\/acesso-a-informacao\/Manual_FalaBr_SIC_versao2.pdf"},{"key":"2026042206250766000_11.4.e021546.25","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.lana.2024.100905","article-title":"Nationwide economic analysis of pulmonary tuberculosis in the Brazilian healthcare system over seven years (2015\u20132022): a population-based study","volume":"39","author":"Barreto-Duarte","year":"2024","journal-title":"The Lancet Regional Health - Americas"},{"key":"2026042206250766000_11.4.e021546.26","unstructured":"Brazilian Central Bank . Citizen inflation calculator. n.d. Available: https:\/\/www3.bcb.gov.br\/CALCIDADAO\/publico\/exibirFormCorrecaoValores.do?method=exibirFormCorrecaoValores"},{"key":"2026042206250766000_11.4.e021546.27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/EDE.0000000000001271","article-title":"Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States","volume":"32","author":"Menzies","year":"2021","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2026042206250766000_11.4.e021546.28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(20)30166-5","article-title":"The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis","volume":"395","author":"Martinez","year":"2020","journal-title":"The Lancet"},{"key":"2026042206250766000_11.4.e021546.29","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328216f441"},{"key":"2026042206250766000_11.4.e021546.30","doi-asserted-by":"crossref","first-page":"102209","DOI":"10.1016\/j.eclinm.2023.102209","article-title":"Comparative effectiveness of interventions for preventing tuberculosis: systematic review and network meta-analysis of interventional studies","volume":"64","author":"Liyew","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026042206250766000_11.4.e021546.31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/M19-3741","article-title":"Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings","volume":"173","author":"Bastos","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026042206250766000_11.4.e021546.32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/tmi.13940","article-title":"Implementation of tuberculosis preventive therapy with INH\u2010Rifapentine (3HP) for latent tuberculosis infection management in household tuberculosis contacts in India: A prospective study","volume":"28","author":"Sharma","year":"2023","journal-title":"Tropical Med Int Health"},{"key":"2026042206250766000_11.4.e021546.33","unstructured":"IMPAACT4TB Consortium, Unitaid Initiative . Implementing shorter TPT regimens: Ethiopia, Indonesia & Tanzania. 2024. Available: https:\/\/www.kncvtbc.org\/en\/2024\/09\/18\/implementing-shorter-tpt-regimens-the-experience-of-indonesia-ethiopia-and-tanzania\/"},{"key":"2026042206250766000_11.4.e021546.34","article-title":"High Tuberculosis Preventive Treatment Uptake and Completion Rates Using a Person-Centered Approach among Tuberculosis Household Contact in Yogyakarta","volume":"8","author":"Felisia","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"2026042206250766000_11.4.e021546.35","unstructured":"Hussain H , Jaswal M , Farooq S , et al . Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment, Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/37083926\/"},{"key":"2026042206250766000_11.4.e021546.36","doi-asserted-by":"crossref","unstructured":"Bhargava A . The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India. Lancet Reg Health Southeast Asia 2024;31. doi:10.1016\/j.lansea.2024.100422","DOI":"10.1016\/j.lansea.2024.100422"},{"key":"2026042206250766000_11.4.e021546.37","doi-asserted-by":"crossref","unstructured":"Bagcchi S . Price cut for drug-resistant tuberculosis medicines. Lancet Infect Dis 2025;25. doi:10.1016\/S1473-3099(25)00242-7","DOI":"10.1016\/S1473-3099(25)00242-7"},{"key":"2026042206250766000_11.4.e021546.38","unstructured":"Secretaria de Vigil\u00e2ncia em Sa\u00fade e Ambiente . Diretrizes nacionais do programa Brasil Saud\u00e1vel - unir para cuidar. 2024. Available: https:\/\/www.gov.br\/participamaisbrasil\/diretrizes-nacionais-do-programa-brasil-saudavel"},{"key":"2026042206250766000_11.4.e021546.39","doi-asserted-by":"crossref","unstructured":"Maciel ELN , Sanchez MN , Cruz AMD , et al . 2024 Brazil\u2019s Pivotal Moment in Public Health: Establishing the Interministerial Committee (CIEDDS) for the Elimination of Tuberculosis and Socially Determined Diseases. Rev Soc Bras Med Trop 57. doi:10.1590\/0037-8682-0597-2023","DOI":"10.1590\/0037-8682-0597-2023"},{"key":"2026042206250766000_11.4.e021546.40","unstructured":"United Nations . Transforming our world: the 2030 agenda for sustainable development | department of economic and social affairs. 2015. Available: https:\/\/sdgs.un.org\/2030agenda"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2025-021546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:26:24Z","timestamp":1776875184000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2025-021546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjgh-2025-021546"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2025-021546","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}